These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26118976)

  • 1. Lack of TAFI increases brain damage and microparticle generation after thrombolytic therapy in ischemic stroke.
    Orbe J; Alexandru N; Roncal C; Belzunce M; Bibiot P; Rodriguez JA; Meijers JC; Georgescu A; Paramo JA
    Thromb Res; 2015 Aug; 136(2):445-50. PubMed ID: 26118976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a TAFI-inhibitor combined with a suboptimal dose of rtPA in a murine thromboembolic model of stroke.
    Durand A; Chauveau F; Cho TH; Kallus C; Wagner M; Boutitie F; Maucort-Boulch D; Berthezène Y; Wiart M; Nighoghossian N
    Cerebrovasc Dis; 2014; 38(4):268-75. PubMed ID: 25401979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice.
    Denorme F; Wyseure T; Peeters M; Vandeputte N; Gils A; Deckmyn H; Vanhoorelbeke K; Declerck PJ; De Meyer SF
    Stroke; 2016 Sep; 47(9):2419-22. PubMed ID: 27470988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator.
    Ribo M; Montaner J; Molina CA; Arenillas JF; Santamarina E; Quintana M; Alvarez-Sabín J
    Stroke; 2004 Sep; 35(9):2123-7. PubMed ID: 15243150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke.
    Kraft P; Schwarz T; Meijers JC; Stoll G; Kleinschnitz C
    PLoS One; 2010 Jul; 5(7):e11658. PubMed ID: 20657835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombolysis in experimental cerebral amyloid angiopathy and the risk of secondary intracerebral hemorrhage.
    Reuter B; Grudzenski S; Chatzikonstantinou E; Meairs S; Ebert A; Heiler P; Schad LR; Staufenbiel M; Hennerici MG; Fatar M
    Stroke; 2014 Aug; 45(8):2411-6. PubMed ID: 25005438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobody.
    Hendrickx ML; Zatloukalova M; Hassanzadeh-Ghassabeh G; Muyldermans S; Gils A; Declerck PJ
    Thromb Haemost; 2014 May; 111(5):824-32. PubMed ID: 24402608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.
    Power A; Epstein D; Cohen D; Bathula R; Devine J; Kar A; Taube D; Duncan N; Ames D
    Cerebrovasc Dis; 2013; 35(1):45-52. PubMed ID: 23428996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue plasminogen activator overdose in acute ischemic stroke patients linked to poorer functional outcomes.
    Sahlas DJ; Gould L; Swartz RH; Mohammed N; McNicoll-Whiteman R; Naufal F; Oczkowski W
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):155-9. PubMed ID: 23375748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombolytic therapy for acute ischemic stroke: risks vs benefits.
    Lindbloom EJ
    J Fam Pract; 2003 Oct; 52(10):757, 761. PubMed ID: 14529595
    [No Abstract]   [Full Text] [Related]  

  • 11. Risk of thrombolytic therapy for acute ischemic stroke in patients with current malignancy.
    Masrur S; Abdullah AR; Smith EE; Hidalgo R; El-Ghandour A; Rordorf G; Schwamm LH
    J Stroke Cerebrovasc Dis; 2011; 20(2):124-30. PubMed ID: 20598579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.
    Wang X; Smith PL; Hsu MY; Tamasi JA; Bird E; Schumacher WA
    J Thromb Thrombolysis; 2007 Feb; 23(1):41-9. PubMed ID: 17111204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency.
    Vercauteren E; Peeters M; Hoylaerts MF; Lijnen HR; Meijers JC; Declerck PJ; Gils A
    J Thromb Haemost; 2012 Dec; 10(12):2555-62. PubMed ID: 23083123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection.
    Muhammad S; Planz O; Schwaninger M
    Cerebrovasc Dis Extra; 2016; 6(2):50-9. PubMed ID: 27560521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. THR-18, a 18-mer peptide derived from PAI-1, is neuroprotective and improves thrombolysis by tPA in rat stroke models.
    Krakovsky M; Polianski V; Nimrod A; Higazi A; Leker RR; Lamensdorf I
    Neurol Res; 2011 Nov; 33(9):983-90. PubMed ID: 22081002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Older age does not increase risk of hemorrhagic complications after intravenous and/or intra-arterial thrombolysis for acute stroke.
    Pundik S; McWilliams-Dunnigan L; Blackham KL; Kirchner HL; Sundararajan S; Sunshine JL; Tarr RW; Selman WR; Landis DM; Suarez JI
    J Stroke Cerebrovasc Dis; 2008 Sep; 17(5):266-72. PubMed ID: 18755405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognosis value of thrombin activatable fibrinolysis inhibitor concentration and C1040T polymorphism in acute myocardial infarction treated with fibrinolysis].
    González FJ; Caturla JM; Fernández M; Carrasco R; Marco P; Sánchez J; Benlloch S
    Med Intensiva; 2010 Nov; 34(8):513-22. PubMed ID: 20627371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
    Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
    Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinase-10 effectively reduces infarct size in experimental stroke by enhancing fibrinolysis via a thrombin-activatable fibrinolysis inhibitor-mediated mechanism.
    Orbe J; Barrenetxe J; Rodriguez JA; Vivien D; Orset C; Parks WC; Birkland TP; Serrano R; Purroy A; Martinez de Lizarrondo S; Angles-Cano E; Páramo JA
    Circulation; 2011 Dec; 124(25):2909-19. PubMed ID: 22104553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of in-hospital mortality and the risk of symptomatic intracerebral hemorrhage after thrombolytic therapy with recombinant tissue plasminogen activator in acute ischemic stroke.
    Al-Khaled M; Matthis C; Eggers J
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):7-11. PubMed ID: 22578915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.